<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320329</url>
  </required_header>
  <id_info>
    <org_study_id>H18-00155</org_study_id>
    <nct_id>NCT04320329</nct_id>
  </id_info>
  <brief_title>Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis</brief_title>
  <official_title>Natural History of Morquio B and Late-Onset GM1 Gangliosidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mucopolysaccharidosis type IVB (Morquio-B disease, MBD) is an autosomal-recessive lysosomal&#xD;
      disease caused by mutations in a gene called GLB1. Clinically, Morquio B presents with&#xD;
      progressive skeletal deformities involving mostly long bones and spine. While the information&#xD;
      on GLB1 mutations associated with MBD is limited, there is a significant overlap in clinical&#xD;
      presentation between Morquio B and late-onset GM1 gangliosidosis with both conditions being&#xD;
      caused by mutations in the same GLB1 gene. In this study, the investigators plan to collect&#xD;
      retrospective data from patients' medical charts, as well as, information from the&#xD;
      prospective follow up clinic visits. There will be two study visits with the interval of one&#xD;
      year. The study procedures will include a detailed physical exam, bone scans, heart and lung&#xD;
      function, physical endurance tests, hearing test, laboratory tests and quality of life&#xD;
      surveys.&#xD;
&#xD;
      The purpose of this study is to collect data on the natural history of Morquio B and to&#xD;
      create a biobank of laboratory samples (blood, urine and skin cells) for future research.&#xD;
      This information will improve the understanding of the natural progression of Morquio B&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to establish the natural history of Morquio B&#xD;
      (Mucopolysaccharidosis type IVB, MBD) disease through the collection and analysis of&#xD;
      retrospective and prospective data on patients diagnosed with Morquio B. Because of&#xD;
      significant overlap in clinical presentation, patients with late-onset GM1 will also be&#xD;
      included.&#xD;
&#xD;
      Upon consent, data from clinical, laboratory, functional and quality of life studies, and&#xD;
      data from review of medical records will be collected and analyzed descriptively. In&#xD;
      addition, the samples of blood, urine and fibroblasts will be collected and stored at BC&#xD;
      Children Hospital Research Institute Biobank for future research. The prospective follow up&#xD;
      will include two clinic visits, one year apart. The following data will be collected during&#xD;
      the prospective observational part of the study (as per study protocol) and retrospective&#xD;
      part (whether such data are available from the medical chart):&#xD;
&#xD;
        -  Medical history: Morquio B / Late-onset GM1 gangliosidosis diagnosis, presentation,&#xD;
           treatments and symptom progression&#xD;
&#xD;
        -  Physical exam, including neurological and ophthalmological assessments&#xD;
&#xD;
        -  Standard Grip Strength Evaluation&#xD;
&#xD;
        -  Range of motion&#xD;
&#xD;
        -  Six-minute walk test (6MWT)&#xD;
&#xD;
        -  3-Minute Stair Climb Test&#xD;
&#xD;
        -  Gait and Motion assessment&#xD;
&#xD;
        -  Pulmonary function testing&#xD;
&#xD;
        -  Hearing test&#xD;
&#xD;
        -  Echocardiography&#xD;
&#xD;
        -  EKG&#xD;
&#xD;
        -  X-ray (lumbar spine, upper &amp; lower limbs, hip)&#xD;
&#xD;
        -  DXA scan&#xD;
&#xD;
        -  Brain MRI&#xD;
&#xD;
        -  Laboratory tests (GAGs assay and pro-inflammatory cytokine panel)&#xD;
&#xD;
        -  Blood, urine and fibroblast samples for biobanking&#xD;
&#xD;
        -  Genetic test (if not done per standard of care)&#xD;
&#xD;
      Additional assessments and evaluations:&#xD;
&#xD;
      â€¢ Patient-reported outcomes: quality of life SF-36, MPS HAQ and the interview on personally&#xD;
      meaningful outcomes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Development</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Height</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Development</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Development</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Growth rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Endurance</measure>
    <time_frame>1 year</time_frame>
    <description>6MWT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Endurance</measure>
    <time_frame>1 year</time_frame>
    <description>3MSCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Endurance</measure>
    <time_frame>1 year</time_frame>
    <description>Standard Grip Strength evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Range of Motion Scale</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Assessments: shoulder, elbow, wrist, hip, knee, ankle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal involvement</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>X-ray studies, pQCT (where available), DXA of lateral distal femur, x-ray and/or MRI of cervical spine to assess spinal stenosis and spinal cord compression; X-ray of cervical spine to assess odontoid hypoplasia and atlantoaxial instability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNS involvement</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Neurological assessments, Brain MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surrogate biomarkers</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Glycosaminoglycans (GAGs): keratan sulfate, heparan sulfate, dermatan sulfate, chondroitin-6-sulfate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surrogate biomarkers</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Comprehensive pro-inflammatory cytokine panel with markers of bone turnover</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related Quality of Life (HRQoL)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>SF-36</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related Quality of Life (HRQoL) and Activities of Daily living (ADLs)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>MPS-HAQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Personally Meaningful Outcomes</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>PMO Questionnaire</description>
  </primary_outcome>
  <other_outcome>
    <measure>Biobank of samples for the future research</measure>
    <time_frame>1 year</time_frame>
    <description>Blood, urine, DBS, fibroblasts (live frozen cells)</description>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Morquio B Disease</condition>
  <condition>GM1 Gangliosidosis Type III</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Urine Dried Blood Spot sample Fibroblasts frozen live cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of any age, any gender with no previous HSCT procedure, with a confirmed diagnosis&#xD;
        of beta-galactosidase deficiency and who clinically present with skeletal dysostosis with&#xD;
        or without CNS involvement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of beta-galactosidase deficiency via demonstration of deficient&#xD;
             enzyme activity and/or demonstration of homozygous/compound heterozygous pathogenic&#xD;
             GLB1 variants;&#xD;
&#xD;
          -  Patients diagnosed with beta-galactosidase deficiency and who present with &quot;MPSIVB&#xD;
             skeletal phenotype&quot; with or without primary CNS involvement;&#xD;
&#xD;
          -  Patient / parent or legal guardian is able to read, understand, and sign the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous Hematopoietic Stem Cell Transplant procedure (HSCT);&#xD;
&#xD;
          -  Concurrent disease or condition that would interfere with participation in the study&#xD;
             and/or travel to the site (for the prospective follow up);&#xD;
&#xD;
          -  Previous or current casual treatments that might affect the natural course of the&#xD;
             disease;&#xD;
&#xD;
          -  Patient's (guardian's) not understanding and/or not agreeing to the informed consent&#xD;
             form;&#xD;
&#xD;
          -  GM1-gangliosidosis patients who present without &quot;MPSIVB skeletal phenotype&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nataliya Yuskiv, Dr</last_name>
    <phone>6048752000</phone>
    <phone_ext>6399</phone_ext>
    <email>nyuskiv@cw.bc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Sylvia Stockler</investigator_full_name>
    <investigator_title>MD, PhD, MBA, FRCPC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gangliosidoses</mesh_term>
    <mesh_term>Gangliosidosis, GM1</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

